Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Net Income towards Common Stockholders: 2018-2019

Historic Net Income towards Common Stockholders for DiaMedica Therapeutics (DMAC) over the last 2 years, with Dec 2019 value amounting to -$2.5 million.

  • DiaMedica Therapeutics' Net Income towards Common Stockholders fell 26.40% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 85.72%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.12% down from last year.
  • According to the latest figures from Q4 2019, DiaMedica Therapeutics' Net Income towards Common Stockholders is -$2.5 million, which was down 1.31% from -$2.4 million recorded in Q3 2019.
  • DiaMedica Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$650,000 during Q1 2018, with a 5-year trough of -$3.3 million in Q1 2019.
  • Its 2-year average for Net Income towards Common Stockholders is -$2.0 million, with a median of -$2.2 million in 2018.
  • Data for DiaMedica Therapeutics' Net Income towards Common Stockholders shows a maximum YoY plummeted of 400.31% (in 2019) over the last 5 years.
  • DiaMedica Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$2.0 million in 2018, then fell by 26.40% to -$2.5 million in 2019.
  • Its last three reported values are -$2.5 million in Q4 2019, -$2.4 million for Q3 2019, and -$2.5 million during Q2 2019.